NCT00184366

Terminated

Classification and Characterization of Patients Treated With...

Norwegian University of Science and Technology Source

Norwegian University of Science and Technology

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

ROCAC

Study Type

observational

Actual enrollment (reported)

96

Locations

1 country

Sites

1

Timeline

Study Start

May 2005

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

May 2008

Actual (reported)

Study Completion

July 2008

Actual (reported)

Brief Summary

The main objectives of the project are:

To classify patients suffering from plaque psoriasis responding on a given treatment (efalizumab) based upon reduction in Psoriasis Area and severity Index (PASI), Psoriasis Disability Index 8PDI) and dermatology Life Quality Index 8 DLQI)
To characterize patients suffering from plaque psoriasis responding to or not responding to subcutaneous administrated efalizumab.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: terminated
Actual enrollment (reported): 96 participants
Study completion date: July 2008
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
May 2005
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
September 13, 2005
Actual (reported)
First Posted
September 16, 2005
Actual (reported)
Primary Completion
May 2008
Actual (reported)
Study Completion
July 2008
Actual (reported)

Last Updated: January 19, 2012
Status Verified: January 2012
Last Update Submitted: January 18, 2012

Conditions

Plaque Psoriasis

Keywords

drug therapyefalizumab

Outcome Measures

Primary Outcomes (1)

Response PASI 75
2 years

Secondary Outcomes (2)

Dermatology Life Quality index (DLQI)
2 years
Psoriasis disability Index (PDI)
2 years

Interventions

efalizumabDrug

efalizumab

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

patients of both genders, over the age of 18 years who have been suffering from moderate to severe plaque psoriasis for more than six months and who are eligible for efalizumab treatment according to current Norwegian guidelines.

You may qualify if:

moderate to severe plaque psoriasis for more than six months

Sponsors & Collaborators

Norwegian University of Science and Technology
Otherlead

Study Sites (1)

Dep of dermatology, St Olavs Hospital

Trondheim, 7006, Norway

MeSH Terms

Interventions

efalizumab

Study Officials

Morten Dalaker, univ lekt II
St Olavs hospital, NTNU, Norway
STUDY CHAIR

Enrollment

96 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 16, 2005

Study Start

May 2005

Date type not reported

This date has not been verified as actual or estimated.

NCT00115076

Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis

Phase 3Completed

NCT00312026

A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Plaque Psoriasis Involving the Hands and/or Feet

Phase 4Completed

SYFe511a3c5edff4c03b1ad0886a646f488

A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoriasis

Phase 2Unknown

NCT00608777

Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)

Phase 4Terminated

NCT00428974

Safety and Efficacy Study of CF101 to Treat Psoriasis

Phase 2Completed

NCT00338143

A Study to Evaluate Efalizumab in Adults With Plaque Psoriasis, Including Those Who Are Receiving Concomitant Antipsoriatic Therapies

Phase 3Completed

eligible for efalizumab treatment according to current Norwegian guidelines

You may not qualify if:

Pregnant or breast-feeding patients
Patients with a history of uncontrolled bacterial, viral, fungal or atypical mycobacterial infection.
Patients suffering from HIV, Hepatitis B or C, active tuberculosis, hepatic cirrhosis and hospital admission for cardiac disease, stroke or pulmonary disease within last year.
Patients with history of cancer in the preceding 5 years, including lymphoproliferative disorders. patients with history of fully resolved basal cell or squamous cell skin cancer may be enrolled.
Patients with impaired renal or hepatic function.

Contact the study team to confirm eligibility.

Primary Completion

May 2008

Actual (reported)

Study Completion

July 2008

Actual (reported)

Last Updated

January 19, 2012

Record last verified: 2012-01

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00184366
Data provider: ClinicalTrials.gov
Source updated: 2012-01-19
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:24:06 UTC

Locations

NO(1)

Study Stopped

Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations